0001708599-26-000035
SEC filingSerina Therapeutics reported a larger net loss of $6.9M in Q1 FY2026 versus $4.8M in Q1 FY2025, reflecting continued investment in clinical development and expanded operations — consistent with management’s expectation of increasing R&D and G&A expenses.
Net income for Q1 FY2026 was -$6.9M, compared to -$4.8M in Q1 FY2025 — a 43.3% increase in loss magnitude. This reflects Serina’s continued prioritization of clinical development, particularly for later-stage candidates like SER-252, where trial size and duration inherently drive higher costs. Management notes that product candidates in later stages of clinical development generally incur higher development costs than earlier-stage programs, a structural dynamic shaping expense growth.
Diluted EPS was -$0.58, down from -$0.49 in the prior-year quarter. While the authoritative packet confirms the EPS values and their year-over-year change (-18.4%), it does not provide the weighted-average diluted share count or its growth rate. However, management’s repeated commentary — including in both the current and prior filings — affirms that share count continues to increase, contributing to EPS dilution alongside higher net losses.
Across multiple disclosures, management states it expects research and development expenses, general and administrative expenses, and capital expenditures to continue increasing. This outlook is grounded in the natural progression of clinical development and operational scaling. The company also reiterates that it will need to delay, reduce, or terminate planned activities if additional capital is not secured — a direct acknowledgment of liquidity constraints and the absence of near-term revenue. Given the inherent uncertainty in pharmaceutical development timelines and funding requirements, management emphasizes it cannot estimate exact future capital needs, underscoring the qualitative nature of forward-looking planning at this stage.